

REMARKS

Claims 1, 4, 5, 11, 12, 15 and 17-27 are pending the application; Claims 1, 4, 5, 11, 12, 15 and 17-27 stand rejected. By this Amendment, Claims 17-18 and 23-26 have been cancelled, and Claims 1, 5, 11, 15, 19 and 22 have been amended. These amendments add no new matter to the application.

Claims 1, 4, 5, 11, 12, 15 and 17-27 stand rejected under 35 USC 112 as allegedly not enabled and/or indefinite; Applicant traverses these rejections. However in the interest of an early arrival at a definition of allowable subject matter, Applicant has made the amendments detailed below. Claims 17-18 and 23-26 have been cancelled without prejudice to their later inclusion and/or prosecution in this or co-pending applications.

Applicant gratefully acknowledges the Examiner's indication of enabled, and therefore presumably allowable, subject matter at page 3, paragraph 7 in the form of "a method for inhibiting or reducing beta-amyloid protein fibril formation by addition of laminin *in vitro* and within cell-free systems." Applicant has amended claims 1 and 15 accordingly to recite "administering to a cell-free system, or an *in vitro* site, containing beta-amyloid protein an effective amount of laminin, or a fragment of a laminin protein." See marked up claims 1 and 15 below.

1. (Currently Amended) A method for inhibiting or reducing beta-amyloid protein fibril formation, deposition or accumulation, the method comprising administering to a cell-free system, or an in vitro site, containing beta-amyloid protein an therapeutically-effective amount of laminin, or a fragment of a laminin protein.

15. (Currently Amended) A method for inhibiting or reducing beta-amyloid protein fibril formation, deposition or accumulation, the method comprising administering to a cell-free system, or an in vitro site, containing beta-amyloid protein an therapeutically-effective amount of

a polypeptide selected from the group consisting of human laminin, mouse laminin, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO 4:, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO: 11, and fragments thereof.

Claim 19 has been amended with a variant on the Examiner's suggested theme, namely reciting administering to "any non *in vivo* site". See marked up claim 19 below.

19. (Currently Amended) A method for inhibiting or reducing beta-amyloid protein fibril formation, deposition or accumulation, the method comprising: administering an ~~therapeutically~~ effective amount of a polypeptide selected from the group consisting of human laminin, mouse laminin, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO 4:, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO: 11, and fragments thereof into any non *in vivo* site containing beta-amyloid protein.

Claims 1, 15 and 19 have also had the objected to word "therapeutically" taken out, as no longer necessary to delimit how much of the laminin fragment to add; and the word "effective" may now be seen to be used in the sense of "effective to cause the previously recited inhibition or reduction."

Claims 5, 11 and 22 have received minor clarifying amendments as set forth below to address the Examiner's concerns over meaning and antecedents.

5. (Currently Amended) The method of claim 1 wherein the beta-amyloid protein fibrils ~~are~~ formation, deposition or accumulation is associated with Alzheimer's disease or Down's syndrome.

11. (Currently Amended) The method of claim 1 wherein the laminin fragment comprises a globular domain repeat within the laminin A chain ~~or a fragment thereof~~.

22. (Currently Amended) The method of claim 15 wherein the beta-amyloid protein fibril formation, deposition or accumulation disease is associated with Alzheimer's disease or Down's syndrome.

Applicant also traverses the Examiner's provisional double patenting rejection as to claims 15 and 20 versus claims 19 and 21. Claim 19 as amended now recites a condition ("a non *in vivo* site) different from that of claim 15 ("a cell-free system, or an *in vitro* site"). Applicant request this provisional rejection be withdrawn.

Applicant believes that all claims are now in compliance with section 112, and are therefore in condition for allowance; reconsideration is therefore requested.

Applicant believes that it has responded fully to all of the concerns expressed by the Examiner in the Office Action, and respectfully requests that early favorable action be taken on all claims pending in the application. Applicant respectfully requests reexamination of all rejected claims and early favorable action on them as well. If the Examiner has any further concerns, Applicant requests a call to Patrick Dwyer at (206) 343-7074.

Respectfully submitted,



PATRICK MICHAEL DWYER
Reg. No. 32,411

PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109

P03-OA3.RSP